That being said, a recent phase 2 trial of intranasal insulin for AD began the trial using the device we used here but switched because of device malfunctions necessitating frequent replacements, and the intent to treat population was changed to focus only on those using the second device [58]. The gene discussed is INS; the disease is Alzheimer disease.